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improves the subsequent pregnancy rate
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Jan Krátký1† and Jan Jiskra1†Abstract
Background: Hypothyroidism and/or autoimmune thyroid disorders (AITD) may contribute to spontaneous
abortions (SpA). Cost-effectiveness analyses of thyroid screening in women after SpA are lacking. Our aim was to
evaluate the cost-effectiveness of screening for AITD and/or hypothyroidism and their treatment in women after
SpA with regard to their reproductive health.
Methods: We performed a cross-sectional non-randomized study with follow-up in 2008–2011 in the settings of
Departments of Endocrinology and Obstetrics/Gynecology of a university hospital. We enrolled 258 women after
SpA before the 12th gestational week and followed them for a median of 3 years. At enrollment, serum concentrations
of thyroid stimulatory hormone (TSH), antibodies to thyroid peroxidase (TPOAb) and free thyroxine (FT4) were
measured and thyroid ultrasound performed. Women with overt hypothyroidism were treated with levothyroxine
(n = 45; 61.6%) and women with subclinical hypothyroidism or euthyroid AITD were treated (n = 28; 38.4%) or left
untreated (n = 38; 14.7%). Euthyroid women without signs of AITD served as controls (n = 147; 57.0%).
Results: Of the 38 untreated women with AITD and/or subclinical hypothyroidism, 8 (21.1%) reported secondary
infertility as compared to 16/147 (10.9%) controls and 3/73 (4.1%) treated women (p = 0.021). Treatment was
associated with an increased rate of successfully completed subsequent pregnancies (increment of 6 newborns/100
women) and a savings of €19,539/100 women. Total costs per successfully completed pregnancy were €1,189 in
controls, €1,564 in the treated, and €2,488 in the untreated women.
Conclusions: Screening for thyroid disorders in women after SpA and treatment with levothyroxine is cost-saving and
it improves the subsequent pregnancy rate.Background
About 10–15% of pregnant women are positive for auto-
antibodies to thyroid peroxidase (TPOAb) [1-3] and up to
5%, depending on the cut-off used, have elevated thyroid
stimulating hormone (TSH) [4,5]. Untreated maternal thy-
roid disease during pregnancy may have a negative impact
on the course of pregnancy and the development of cogni-
tive function of the offspring [6,7]. Women with elevated
TPOAb could have increased rates of infertility [8], mis-
carriage [9-11] and perinatal death [12]. Additionally,* Correspondence: bartakovaj@gmail.com
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reproduction in any medium, provided the ordiagnosis and treatment of women with unrecognized
hypothyroidism and euthyroid autoimmune thyroid dis-
ease (AITD) seem to be effective in preventing repeated
spontaneous abortions (SpA) [13,14]. However, laboratory
screening for thyroid disorders immediately after SpA is
not recommended, except in cases of a subsequent preg-
nancies [15]; and in women after recurrent SpA in clinic-
ally suspected cases [16]. Although studies have been
published on the cost-effectiveness of the thyroid screen-
ing in pregnant women [17-19], no study has assessed the
clinical importance and cost-effectiveness of screening for
thyroid disorders in women after SpA until now.
The aims of our study were: A) to evaluate the course
and outcome of a subsequent pregnancy in women with
AITD and/or hypothyroidism after SpA with regard toral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effectiveness analysis to assess the suitability of laboratory
screening for AITD and/or hypothyroidism in women
after SpA from the perspective of women’s reproductive
health (the time to conceive, natural vs. medically assisted
conception, physiological delivery in term, premature de-
livery, caesarean section - SC, SpA, secondary infertility).
Methods
Patients and controls
The study was performed in the settings of Departments of
Endocrinology and Obstetrics/Gynecology of the General
University Hospital and the First Medical Faculty of the
Charles University in Prague. It was designed as a cross-
sectional non-randomized study during the post-abortion
follow-up.
In years 2008–2011, serum concentrations of TSH,
TPOAb and free thyroxine (FT4) were investigated and
thyroid ultrasound (TUS) performed in 297 consecu-
tively chosen women after SpA before the 12th gesta-
tional weeks. Serum FT4 was measured only if TSH
and/or TPOAb were abnormal. Median time of examin-
ation was 4 weeks after SpA. The investigated group
consisted of all women who had SpA at the time of this
project. The study was approved by the local Ethical
Committee and all women signed an informed consent
form (Ethics Committee of the General University Hos-
pital, Prague).
We created a standardized scheme of endocrine care of
women after SpA for the purposes of the study (Figure 1).
Based on the findings in serum levels of TSH, TPOAb,
FT4 and TUS, we decided whether to treat them with
LT4. As positive in screening, women already treated with
LT4 for thyroid diseases and women with newly diagnosed
positive laboratory finding and autoimmune pattern on
TUS were regarded. Overt hypothyroidism was defined as
serum TSH >4.0 mIU/l with decrease in FT4 (<9.8 pmol/l);
subclinical hypothyroidism as TSH >4.0 mIU/l and nor-
mal serum FT4 (9.8-23.1 pmol/l) and euthyroid AITD was
defined as normal TSH (0.4-4.0 mIU/l) with markedly
positive TPOAb (>254.4 kIU/l) or borderline positive
TPOAb (60–254.4 kIU/l) and autoimmune pattern in
TUS. Cut-off for markedly positive TPOAb was deter-
mined as 90th percentile of serum concentration within
group of 297 unselected included women. Borderline posi-
tivity was defined as TPOAb concentration between upper
limit of manufacturer (60 kIU/l) and the 90th percentile
(254.4 kIU/l). LT4 treatment was obligatorily started in
overt hypothyroidism and subclinical hypothyroidism with
positive TPOAb. In euthyroid AITD and subclinically
hypothyroid women with negative TPOAb, LT4 treatment
was started on individual basis. In these cases the treat-
ment was started if at least one of the following criteria
were met: TSH >10 mIU/l; autoimmune pattern on TUS;and symptoms of hypothyroidism; or if the patient wished
to be treated. Every endocrine check-up included a visit in
the office of the endocrinologist (except in case of a
check-up within six weeks, which was done by a telephone
consultation) and a laboratory test of TSH. At the time of
follow-up, 73 women were treated with LT4 for
hypothyroidism or euthyroid AITD (group “Treated”, me-
dian age 33 years). From them, 45 women have been
already treated and in 28 the treatment was newly intro-
duced after SpA (8 for hypothyroidism and 20 for euthyr-
oid AITD). There were no women after thyroidectomy or
without signs of thyroid autoimmunity at TUS and nega-
tive TPOAb in group Treated. Thirty-eight women had
euthyroid AITD and/or subclinical hypothyroidism with-
out treatment (group “Untreated”, median age 32 years).
Finally, 147 women were negative in thyroid laboratory
screening and TUS (“Controls”, median age 33 years).
Range of the standardized initial dosage of LT4 was 50–75
ug/day (median 51.34 ug/day). At the time of follow-up in
the Treated group the laboratory tests were done. The tar-
get TSH (0.5-2.5 mIU/l) was achieved (median 1.36 mIU/l,
range 0.52–2.37 mIU/l). There were no cases of over-
treatment. For simplicity, further adjustment of the LT4
dosage to achieve the target TSH was not considered in
the economic analysis.
At follow-up, we interviewed the women by telephone
and we filled a questionnaire on the women’s history
and reproductive health (19 questions including the time
to conceive, natural vs. medically assisted conception,
physiological delivery in term, premature delivery, SC,
SpA, secondary infertility). As a physiological delivery at
term, delivery in the 38th–42nd gestational weeks was
elected. Premature delivery was defined as delivery be-
fore the end of 37th gestational week. For the purposes
of our study, secondary infertility was defined as a lack-
ing success in attempted conception during the time be-
tween the last SpA and data collection and analysis.
Although the Czech Republic belongs to the iodine
sufficient countries [20], we advised all women after the
reference SpA to use iodine supplementation of 100–
150 ug/day before and during next pregnancy.
Laboratory methods
Serum concentrations of TSH, TPOAb and FT4 were
determined by chemiluminiscence method (ADVIA®
Centaur™, Bayer, Germany). The reference intervals were
determined by the manufacturer (TSH: 0.40-4.00 mIU/l,
TPOAb: <60 kIU/l and FT4: 9.80-23.10 pmol/l). Using
the manufacturer’s cut-off level for TPOAb, we found
36.4% of the women to be positive for TPOAb. Overall,
55.0% of the women had a positive laboratory finding
(pathological TSH and/or TPOAb). Therefore, we de-
cided to use a different upper cut-off limit for TPOAb:
254.4 kIU/l, as determined by Springer as the 90th
Figure 1 Flowchart of standardized endocrine follow-up of women after spontaneous abortion. Retrospective view. SpA, spontaneous
abortion; LT4, levothyroxine; AITD, autoimmune thyroiditis.
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women [3].
Thyroid ultrasound
The study participants underwent TUS examination
within 9 weeks after SpA. We used the ultrasound device
EnVisor (Philips) with an 8–12 MHz linear probe (model
PLF-805ST), allowing maximum examination depth of
40 mm at a frame rate of 19 Hz. In order to eliminate the
inter-individual variability, TUS examinations were per-
formed by only one experienced physician. Ultrasound
evaluation was made on the basis of hypoechogenicity, ir-
regular echo pattern and the presence of nodules. In case
of thyroid texture, we used our previously published semi-
quantitative evaluation model [21]. Autoimmune pattern
in TUS was determined as hypoechogenicity and inhomo-
geneity of the thyroid parenchyma.
Statistical analysis
Statistical software Sigmastat (Jandel Scientific, San
Rafael, CA, USA) was used for data analysis. The Chi-
square test, Fischer test and ANOVA on ranks (Dunn’s
method) were used to compare the proportions, means
and medians between the groups. In order to assess the
influence of the variables on the p-value in the Chi-
square test in the contingency table, we used the Chi-
square test of independence [22]. All reported p-values
are two-side and p < 0.05 was considered as statistically
significant. Throughout the text, data are expressed as
mean (± standard deviation) or as median (range).
Economic analysis
We used the cost-effectiveness analysis (CEA) for eco-
nomic evaluation. CEA compares the costs and health
effects of an intervention in order to assess the extent to
which it can be regarded as providing value for money.Table 1 Total costs on the pregnancy outcomes
Physiological delivery Pr
Discount factor 1.000
Number of women Treated 24
Untreated 10
Controls 52
Total unit costs (€) Treated 389
Untreated 346
Controls 282
Total Costs (€) Treated 9,334
Untreated 3,805
Controls 14,386
Discount factors were chosen on the relationship of the average time in the group
subsequent pregnancy). There was no different in average time between the subgr
for thyroid disease, regular endocrine controls, LT4 treatment and costs of pregnan
time horizon 4 years prospective, payer’s perspective. SpA, spontaneous abortion; SThe costs were estimated from the payer’s (health insur-
ance) perspective. We determined the time horizon as
the maximum time of the intended follow-up after SpA
(four years prospective). Based on estimated published
fiscal outlook of the Czech Republic’s Ministry of Fi-
nance [23], we assumed the discount rates to be 3%
using 2012 unit costs. For the next years, we calculated
the present value of a sum of a spent money by using
discount rates and the time horizon [24]. We based the
calculation of the discounting costs of end of pregnancy
(physiological delivery in term; premature delivery; cae-
sarean section; SpA) on the median time between the
reference SpA and the end of the next pregnancy
(Table 1). There were no differences in this median time
between the groups. We discounted the costs of second-
ary infertility in the same way. The considered costs
were defined as the medical costs directly related to
treatment of an individual woman. The costs included
medical visits (Depts. of Endocrinology and Obstetrics
and Gynecology), laboratory tests and other examinations
(e.g. ultrasonography, cardiotocography), administered
drugs and days of hospitalization. We calculated the costs
of medical check-ups, laboratory tests and examinations
based on data extracted from the legislation administered
by the Czech Ministry of Health (Decree No. 411/2011;
Decree No. 439/2008; Decree No. 472/2009; Decree No.
425/2011) and we also used the payment algorithm
(Decree No. 439/2008) of the same Ministry. In case of
hospital care, we also included costs of hospitalization
valid in the General University Hospital in Prague. We es-
timated the length of hospitalization as the average time
linked to individual modes of pregnancy ending in our
hospital. In order to calculate the prices of drugs adminis-
tered, we used the database of The State Institute of Drug
Control in the Czech Republic [http://www.sukl.cz/mod-
ules/medication/search.php?lang=1] and extracted theemature delivery SC SpA Secondary infertility
1.000 1.000 1.000 0.971
4 10 23 3
2 4 9 8
8 24 20 16
402 493 287 1,516
359 450 244 1,473
295 386 180 1,409
1,608 4,929 6,607 4,547
718 1,799 2,442 11,782
2,362 9,265 3,428 22,543
of women after SpA (time from the reference SpA to the termination of
oups Treated, Untreated and Controls. The costs included the costs of screening
cy outcomes. Costs are calculated as a weighted average. Discount rate 3%,
C, section cesarean.
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are stated in Additional file 1.
We excluded women from the economic evaluation
who did not try to get pregnant again after the SpA, as
well as the currently pregnant women (we could not an-
ticipate the pregnancy outcome). We considered a suc-
cessfully ended pregnancy as a physiological delivery of a
live newborn at term. We did not include costs due the
newborn in the economic analysis.
Health economic models
For estimation of the final costs and effects, we created
a patient-based health economic model in which we
tested the costs and effects of treatment and screening.
The standardized endocrine follow-up of women after
SpA is shown in Figure 1. Costs associated with preg-
nancy outcome (Additional file 1) are based on a model
of a standardized process in the General University Hos-
pital in Prague according to the actual outcome of the
next pregnancies in groups analyzed (Table 1).
We calculated the assessment of costs related to treat-
ment of an infertile woman with the use of the costs of
the standard methods of infertility treatment used in our
hospital. The In Vitro Fertilization (IVF) and the method
of an Artificial Insemination by Husband (AIH) were
calculated in the ratio of use 5:1. We calculated the aver-
age costs of ovulation stimulators per cycle of IVF
(clomiphene or tamoxiphen) and average costs of follicle
stimulating hormone per cycle in case of AIH.
In the analysis, we calculated the cost of four bed-days
in the Dept. of Obstetrics and Gynecology in case of a
physiological delivery; of five bed-days in case of preterm
delivery and caesarean section (SC) and of one added bed-
day in an Intensive Care Unit in case of SpA and SC.
All costs were converted to EUR with an approximate
exchange rate in 2012 (1 CZK = 0.047 EUR).Table 2 Basal characteristics of the study participants at the t
Treated with levothyroxin
Before SpA Newly a
n 45 2
Age (years) 33 3
BMI 22.29 21
Family history of thyroid disease 19 (42%) 10 (
Autoimmune pattern in TUS 10 (22%) 23 (
FT4 (pmol/l) 14.75 (11.70-22.20) 14.20 (11
TSH (mIU/l) 1.84 (0.51-7.32) 2.26 (0.
TPOAb (kIU/l) 68.00 (15.00-4480.00) 118.00 (33.
Subclinical hypothyroidism - 8 (2
Euthyroid AITD - 20 (
The values are expressed as median (range). SpA: spontaneous abortion; TUS: thyro
concentration of thyroid stimulating hormone; TPOAb, serum concentration of antib
ranks (except women with family history of thyroid disease and autoimmune patterResults
From the 297 women included, 39 were lost to follow-
up (one Treated, six Untreated and thirty-two Controls).
At the time of follow-up (median 38 months, range: 8 –
47 months), 258 provided data concerning their subse-
quent reproductive health.
Of the 258 women analyzed, 111 (43.0%) were positive
for thyroid disorders and 147 (57.0%) were negative. Of
the 111 positive women, 45 (40.5%) had already been
treated for hypothyroidism and/or AITD before inclu-
sion in the study and 66 (59.5%) were newly diagnosed.
Of the 66 newly diagnosed positive women, 15 (13.5%)
had hypothyroidism (TSH >4.0 mIU/l) and/or markedly
positive TPOAb, 26 (31.5%) had markedly positive
TPOAb and normal TSH and 25 (22.5%) had borderline
positive TPOAb and autoimmune pattern on TUS. Mean
age at the current SpA was 32.52 ± 4.42 years and mean
gestational age at the time of SpA was 9.15 ± 2.53 weeks.
In 94 (36.4%) women, this was the first pregnancy; 118
(45.7%) had previous history of delivery of a live off-
spring and 91 (35.3%) had previous history of one or
more SpA (70.3% one miscarriage, 22.0% two miscar-
riages, 7.7% three or more miscarriages). After the
current SpA, the median of time to next conception was
7 months (range: 1 – 43 month) and the median of dur-
ation of secondary infertility was 26 months (range: 12 –
47). Baseline characteristics of women after SpA are
shown in Table 2.
Relationship of thyroid diseases and reproductive health
Thirty-one women who did not wish to conceive again
and twenty women who were pregnant at the time of
data collection were excluded from analysis.
The rates of secondary infertility among all positive
women together (Treated and Untreated) and Controls
were similar [11/111 (9.9%) vs. 16/147 (10.9%), p = 0.926].ime of spontaneous abortion
e Untreated Controls p-value
fter SpA
8 38 147
4 32 33 0.314
.94 23.42 21.34 0.698
36%) 14 (37%) 37 (25%) 0.118
82%) 30 (73%) 0 (0%) <0.001
.30-20.60) 13.80 (11.00-17.50) 14.40 (11.10-20.20) 0.278
89-8.88) 1.91 (0.30-4.52) 1.54 (0.58-3.94) 0.002
00-2820.00) 42.50 (22.00-1805.00) 41.00 (0.00-163.00) <0.001
8%) 13 (34%) - 0.827
71%) 25 (66%) - 0.827
id ultrasound; FT4, serum concentration of free thyroxin; TSH, serum
odies to thyroid peroxidase; AITD, autoimmune thyroid disorders. ANOVA on
n in TUS: Chi-square test).
Figure 2 Costs-effectiveness analysis. A, Number of successfully completed pregnancies per women; B, total costs per women; C, costs per
one successfully completed pregnancy.
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ity to conceive with methods of assisted reproduction be-
tween positive women and Controls.
Treated women had significantly lower rate of second-
ary infertility as compared to Controls and Untreated
women [3/73 (4.1%) vs. 16/147 (10.9%) vs. 8/38 (21.1%),
p = 0.021].
We did not find any significant effect of LT4 treatment
on the frequency of subsequent SpA, SC and premature de-
liveries. Numbers of women in each group with respect to
the subsequent pregnancy outcome are shown in Table 1.Costs
From the perspective of health insurance, unit costs of
screening for thyroid disease in women after SpA
(thyroid laboratory and TUS examination) were €27.05.
The discounted unit costs from prospective of four years
were calculated in the Treated group to be €150.94, in
the Untreated group €107.88 and in the Control group
€44.09 EUR. The costs included the costs of screening for
thyroid disease, regular endocrine controls and LT4 treat-
ment. Pregnancy outcomes and appropriate discountfactors used depending on the median of the years in the
group of women after SpA are shown in Table 1.Costs-effectiveness analysis
Treatment of AITD and/or hypothyroidism was associated
with an increased rate of successfully completed next
pregnancies (increment of 6 newborns/100 women) and
to savings of €19,539/100 women. Total costs per success-
fully completed pregnancy were €1,189 in Controls, €1,564
in Treated, and €2,488 in Untreated (Figure 2).
The total cumulative costs of healthcare associated
with reproduction during four years in women with
AITD and/or hypothyroidism were significantly lower if
they were treated with LT4 (Table 1).
In the group of women after SpA, four patients (one
Treated and tree Controls) had premature delivery with
SC. In order to avoid double counting of costs for these
patients, we subtracted the costs of thyroid screening, a
possible LT4 treatment and follow-up endocrine controls
and cost of premature delivery from the cumulative total
costs of overall healthcare. Moreover, we added cost
of methods of assisted reproduction in women who
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Treated, five Untreated and seven Controls). We used an
appropriate discount factor (0.971) depending on the
median time to conceive again after SpA (2 years).
Discussion
The recent years have witnessed a fierce debate on the
topic of screening for thyroid diseases in pregnancy, in-
cluding several cost-effectiveness analyses [17-19]. SpA
belongs among the principal negative outcomes of un-
treated thyroid disorders in pregnancy. However, studies
on thyroid screening in women after SpA in relation to
the subsequent pregnancy are lacking. Our study pre-
sents the first cost-effectiveness analysis of thyroid
screening in women after SpA.
Although women with pathological values in thyroid
screening after SpA did not have a significantly higher rate
of secondary infertility then women screened negatively,
in the subgroup analysis targeted at LT4 treatment in
women with AITD and/or hypothyroidism we achieved
striking results: treated women had significantly lower
rates of secondary infertility (21.1% vs. 4.1%) and increased
rates of physiological deliveries (increment of 6 newborns/
100 women) as compared to women untreated. Moreover,
treatment with LT4 led to savings of €19,539/100 women
from the time horizon of four years.
Our results are in line with findings of the recent ran-
domized study of Kim et al. [25] who demonstrated that
embryo implantation rate and live birth rate is signifi-
cantly higher in women with subclinical hypothyroidism
who were treated with LT4. Moreover, Zhung et al. eval-
uated 90 anti-thyroid antibody positive women and 676
anti-thyroid antibody negative infertile women undergo-
ing IVF. They present evidence that the presence of
anti-thyroid antibodies decreases fertilization rate, im-
plantation rate and pregnancy rate [26]. On the contrary
to the study of Negro et al. [13], we did not find signifi-
cant beneficial influence of LT4 treatment on the pre-
term delivery and recurrent SpA, but our study was not
designed to study these effects and it was not random-
ized. Similarly, in contrast to study of Negro et al. [27]
who analyzed women undergoing IVF, we observed in-
creased rates of physiological deliveries in women
treated with LT4; however, our study wasn’t targeted at
women undergoing IVF.
Although a number of studies have shown a link be-
tween thyroid disorders and an increased risk of recur-
rent SpA [28-30] and secondary infertility [29,31-33], we
found only a non-significant trend to higher rates of sec-
ondary infertility or recurrent SpA among women with
laboratory findings of AITD and/or hypothyroidism in
comparison to women with normal laboratory results.
This probably might be due to the fact that we analyzed
women treated with LT4 already before SpA togetherwith newly diagnosed positive women. When we ana-
lyzed previously just untreated positive women, we
found significantly lower rate of secondary infertility in
Treated group as compared to Controls and Untreated
group. Moreover, rate of infertility was even lower in
Treated group as compared to Controls. We suppose
that this could be not only due to effect of levothyroxine
treatment but, moreover, due to more accurate iodine
supplementation in the Treated group in comparison
with Untreated and Controls. Treated women were
under the supervision of an endocrinologist and this fact
could lead to more compliant using not only of levothyr-
oxine, but also of iodine supplementation. As reported
in literature, iodine supplementation before and during
pregnancy can lead to increased fertility rate [34,35].
The main topic of our study was the cost-effectiveness
analysis of screening for thyroid diseases in women after
SpA. Based on time horizon of four years, we calculated
the costs of screening, endocrine follow-up and treat-
ment; and the costs of achieving the next conception
leading to the successful delivery of a live newborn. The
costs of single screening (TSH, TPOAb and TUS) was
€27.05 per woman in our study; however, in routine
practice the screening would probably be performed
only by measuring TSH and TPOAb, thus decreasing
the costs of a single screening to €18.36 per woman.
The costs associated with long-term use of LT4 were
only €8.98 per women per year. The costs of endocrine
follow-up in positively screened women were €35.09 per
woman for the first year and €13.21 per women per
every additional year. Taken together, the costs associ-
ated with screening and treatment of AITD and/or
hypothyroidism are very low as compared to treatment
of infertility, where the highest costs were incurred by
the methods of assisted reproduction. For example, one
cycle of in vitro fertilization cost €1,586 per woman.
Thus, it is evident that any decrease of infertility rates
among women with thyroid disorders (achieved with
LT4 treatment) may lead to truly significant financial
savings. Moreover, our data show that LT4 treatment of
AITD and/or hypothyroidism leads to an increase in
successfully completed pregnancies (6 children/100
women; compared with untreated women) and to saving
of €19,539/100 women from the time horizon of four
years. It is thus apparent that LT4 treatment of women
with AITD and/or hypothyroidism has a positive impact
on their subsequent pregnancy rate; it is inexpensive and
cost-saving.
Our study has several important strengths. Our health
economic model used real data from patients, unlike the
other cost-effectiveness studies [17-19] which use eco-
nomic models based on transfer of results of other stud-
ies or expert estimates. It takes into account not only
individual characteristics of patients, such a laboratory
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assisted reproductive technology, but also specific char-
acteristics which vary in different geographic area. More-
over, our calculation was based on the real costs
accounted for in our hospital and stated by the Decrees
of the Czech Ministry of Health. The cost-effectiveness
of screening and treatment of thyroid disorders might be
underestimated in our study, as we have not included
some other potential benefits (e.g. improvement of the
quality of life of treated women). Furthermore, even
though the previously published studies demonstrated
that the costs associated with premature birth are enor-
mous [36], our calculated costs are low and approaching
the costs incurred by physiological delivery. This is due
to the fact that we evaluated costs related only to the
treatment of the woman, but not to the neonatology care
of the premature newborn, the increased morbidity of
prematurely born children and also their further prob-
lems in learning and behavior [37].
Our study has several limitations. The main are the
non-randomized design and a small number of women
included (n = 258). Nevertheless, group consisted of all
women who had miscarriage before the 12th gestational
weeks at the time of this project. A further limitation
is that the group of women treated before entering
the study and the group of women with treatment intro-
duced after SpA were analyzed together, similarly as un-
treated and treated positive women. The reason was to
achieve an adequate number of women for statistical
analysis. For all that, we deal with real costs associated
with successful completion of the next pregnancy within
the next four years after SpA. In addition, to make a
clear economical model, we used simplification in case
of LT4 treatment, where the further adjustment of LT4
dosage was not considered. However the costs of LT4
were minor (as was discussed above) and hence we an-
ticipate that the omitting of future adjustment of LT4
dosage does not have a significant impact on the results
of the study. We believe that our results provide a solid
basis for future studies and considerations regarding the
screening for thyroid disorders in women after SpA.Conclusion
In conclusion, our data indicate that screening for thy-
roid disorders in women after SpA and a consequent
treatment with LT4 improve the subsequent pregnancy
rate of women affected. Treatment with LT4 may reduce
the necessity of methods of assisted reproduction in
achieving the next pregnancy. Therefore, inclusion of
systematic screening of TSH and TPOAb in the standard
of care of all women after SpA might not only return
the invested financial means of health insurance, but
even lead to savings in long-term indicators.Additional file
Additional file 1: Unit costs of healthcare services. The costs for
medical check-ups, laboratory tests and other examinations were
calculated by using payment algorithm (Decree No. 439/2008) and by
using data extracted from the legislation administered by the Czech
Ministry of Health (Decree No. 411/2011; Decree No. 439/2008). The costs
of drugs administered were calculated by using the database of The State
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